Live Analyst Rating Changes 24491 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Sudan Loganathan
STEP

Sudan Loganathan

Stephens
Wall Street Analyst
★★★★★
#228
on 13Foresight · ranked by our own returns
72%
Success Rate
+45.5%
Average Return
13 of 18 calls profitable · +30.7% vs benchmark
S&P 500 (SPY)
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 72% of Sudan Loganathan's ratings turned a profit when each position was held for 1 year — averaging +45.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

14 Buy 2 Hold 0 Sell
Sudan's Stock Coverage 17 ratings · 2026-08-14
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
ADCT
ADC Therapeutics
 Jun 04, 2026 BUY Buy
+472.1% avg upside
12 analysts
$5.00
376.14% Upside
 -20.4% ·
PVLA
Palvella Therapeutics
 May 11, 2026 BUY Strong Buy
+7.7% avg upside
27 analysts
$220.00
40.51% Upside
 +27.2% ·
IMNM
Immunome
 Mar 04, 2026 BUY Strong Buy
+27.7% avg upside
16 analysts
$30.00
13.49% Upside
 +16.6% ·
KYMR
Kymera Therapeutics
 Mar 02, 2026 BUY Strong Buy
-7.7% avg upside
37 analysts
$100.00
12.54% Downside
 +28.3% ·
ARVN
Arvinas Holding Company
 Feb 25, 2026 BUY Buy
+217.9% avg upside
28 analysts
$18.00
99.77% Upside
 -34.1% ·
APGE
Apogee Therapeutics
 Dec 17, 2025 BUY Buy
-5.3% avg upside
19 analysts
$95.00
29.30% Downside
 +78.2% ·
PYXS
Pyxis Oncology
 Nov 24, 2025 BUY Strong Buy
+141.1% avg upside
14 analysts
$8.00
165.83% Upside
 -40.4% ·
CADL
Candel Therapeutics
 Oct 28, 2025 BUY Strong Buy
+55.7% avg upside
11 analysts
$15.00
27.14% Upside
 +110.5% ·
CCCC
C4 Therapeutics
 Sep 15, 2025 BUY Strong Buy
+337.3% avg upside
19 analysts
$6.00
47.11% Upside
 +11.5% ·
FTH
Faeth Therapeutics
 Jun 30, 2025 BUY Strong Buy
+56.7% avg upside
16 analysts
$35.00
22.67% Upside
 +191.4% ·
EXEL
Exelixis
 Jun 24, 2025 BUY Buy
-13.9% avg upside
34 analysts
$60.00
18.60% Upside
 +15.6% ·
NRIX
Nurix Therapeutics
 Apr 09, 2025 BUY Strong Buy
+19.2% avg upside
28 analysts
$30.00
10.28% Upside
 +69.2% ·
ATNM
Actinium Pharmaceuticals
 Nov 19, 2024 BUY Strong Buy
+724.0% avg upside
11 analysts
$5.00
418.79% Upside
 -4.2% ·
FENC
Fennec Pharmaceuticals
 Nov 18, 2024 BUY Strong Buy
+36.0% avg upside
9 analysts
$15.00
24.40% Upside
 +117.1% ·
IDYA
IDEAYA Biosciences
 Nov 18, 2024 BUY Strong Buy
+31.9% avg upside
29 analysts
$51.00
39.11% Upside
 +28.7% ·
BCYC
Bicycle Therapeutics
 Nov 07, 2024 HOLD Strong Buy
+490.0% avg upside
21 analysts
$25.00
528.17% Upside
 -73.9% ·
DCTH
Delcath Systems
 May 13, 2024 BUY Strong Buy
+26.9% avg upside
11 analysts
$25.00
43.98% Upside
 +183.1% ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Sudan Loganathan — Frequently Asked Questions
How accurate are Sudan Loganathan's stock ratings?
Based on the calls 13Foresight could measure, about 72% of Sudan's ratings were profitable over a one-year hold, with an average return of +46.0% per rating, or +31.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Sudan ranked on 13Foresight?
Sudan Loganathan is currently ranked #228 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Sudan cover?
Sudan most recently has ratings on ADCT, PVLA, IMNM, KYMR, ARVN, APGE, PYXS, CADL, CCCC, FTH, EXEL, NRIX and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.